Toxic megacolon associated with Clostridium difficile infection recurrence: a case report complicated by multiple bacterial infections and successfully treated with oral fidaxomicin

Addolorata Masiello, Mario Magliocca, Giuseppina Dell’Aquila, Patrizia Maio, Sergio Giglio, Nicola Acone

DOI: https://doi.org/10.7175/cmi.v8i1S.957

Abstract

Toxic megacolon is a severe complication of Clostridium difficile infection (CDI) with a high percentage of mortality. The mainstay of treatment is currently represented by medical management, while surgical intervention is indicated in patients not improving after 2-3 days of antibiotic therapy. Generally metronidazole and vancomycin are administered as first-line treatment, but recently several cases of refractory C. difficile have made the treatment of this infection more difficult. Fidaxomicin is a narrow-spectrum oral macrocyclic antibiotic with excellent in vitro activity against C. difficile strains. We report the case of a woman admitted with a diagnosis of toxic megacolon complicating a C. difficile colitis not responding to standard antibiotic therapy.

Keywords

Toxic megacolon; Clostridium difficile; Fidaxomicin

Full Text

HTML PDF

References

  • Kazanowski M, Smolarek S, Kinnarney F, et al. Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities-a systematic review. Tech Coloproctol 2014; 18: 223-32; http://dx.doi.org/10.1007/s10151-013-1081-0
  • To KB, Napolitano LM. Clostridium difficile Infection: Update on diagnosis, epidemiology, and treatment strategies. Surg Infect (Larchmt) 2014; 15: 490-502; http://dx.doi.org/10.1089/sur.2013.186
  • Zhou FF, Wu S, Klena JD, et al. Clinical characteristics of Clostridium difficile infection in hospitalized patients with antibiotic-associated diarrhea in a university hospital in China. Eur J Clin Microbiol Infect Dis 2014; 33: 1773-9; http://dx.doi.org/10.1007/s10096-014-2132-9
  • Lee YC, Wang JT, Chen AC, et al. Changing incidence and clinical manifestations of Clostridium difficile-associated diarrhea detected by combination of glutamate dehydrogenase and toxin assay in Northern Taiwan. J Microbiol Immunol Infect 2012; 45: 287-95; http://dx.doi.org/10.1016/j.jmii.2011.12.001
  • Cober ED, Malani PN. Clostridium difficile infection in the “oldest” old: clinical outcomes in patients aged 80 and older. J Am Geriatr Soc 2009; 57: 659-62; http://dx.doi.org/10.1111/j.1532-5415.2009.02182.x
  • Vonberg RP, Kuijper EJ, Wilcox MH, et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microb Infect 2008; 14 (S5): 2-20; http://dx.doi.org/10.1111/j.1469-0691.2008.01992.x
  • Arumilli BR, Koneru P, Fayyaz I. Toxic megacolon from hypervirulent Clostridium difficile infection (ribotype 027) following elective total knee replacement: an emerging challenge in modern health care. BMJ Case Rep 2010; 2010. pii: bcr06.2009.2017; http://dx.doi.org/10.1136/bcr.06.2009.2017
  • Griniatsos J, Dimitriou N, Tyritzis, et al. Toxic megacolon due to fulminant Clostridium difficile colitis. Acta Gastroenterol Belg 2011; 74: 359-60
  • Sayedy L, Kothari D, Richards RJ. Toxic megacolon associated Clostridium difficile colitis. World J Gastrointest Endosc 2010; 2: 293-7; http://dx.doi.org/10.4253/wjge.v2.i8.293
  • McMullen TP, Bailey RJ. Advances in the diagnosis and management of toxic megacolon. Can J Gastroenterol 2005; 19: 163-4
  • Gerding DN, Muto CA, Owens RC. Treatment of Clostridium difficile Infection. Clin Infect Dis 2008; 46: S32-S42; http://dx.doi.org/10.1086/521861; http://dx.doi.org/10.1086/521860
  • Cocanour CS. Best strategies in recurrent or persistent Clostridium difficile infection. Surg Infect (Larchmt) 2011; 12: 235-9; http://dx.doi.org/10.1089/sur.2010.080
  • Bass SN, Bauer SR, Neuner EA, et al. Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection. J Hosp Infect 2013; 85: 22-7; http://dx.doi.org/10.1016/j.jhin.2012.12.019
  • Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect 2014; 20 Suppl 2: 1-26; http://dx.doi.org/10.1111/1469-0691.12418
  • O’Horo JC, Jindai K, Kunzer B, et al. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection 2014; 42: 43-59; http://dx.doi.org/10.1007/s15010-013-0496-x
  • DuPont HL. Challenges and opportunities in the management of Clostridium difficile infection. Expert Rev Gastroenterol Hepatol 2014; 8: 863-74; http://dx.doi.org/10.1586/17474124.2014.939630
  • Chahine EB, Sucher AJ, Mantei K. Fidaxomicin: A novel macrolide antibiotic for Clostridium difficile Infection. Consult Pharm 2014; 29: 614-24; http://dx.doi.org/10.4140/TCP.n.2014.614
  • Scott LJ. Fidaxomicin: a review of its use in patients with Clostridium difficile infection. Drugs 2013; 73: 1733-47; http://dx.doi.org/10.1007/s40265-013-0134-z
  • Esmaily-Fard A, Tverdek FP, Crowther DM, et al. The use of fidaxomicin for treatment of relapsed Clostridium difficile Infections in patients with cancer. Pharmacotherapy 2014; 34: 1220-5; http://dx.doi.org/10.1002/phar.1479
  • Nathwani D, Cornely OA, Van Engen AK, et al. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother 2014; 69: 2901-12; http://dx.doi.org/10.1093/jac/dku257
  • Cornely OA, Nathwani D, Ivanescu C, et al. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 2014; 69: 2892-900; http://dx.doi.org/10.1093/jac/dku261

Statistics

Abstract: 1607 views
HTML: 2181 views
PDF: 529 views

Refbacks

  • There are currently no refbacks.